AG真人官方

H1 2025 results: Total revenue rose 11% CER to $28.0 bn, led by Oncology (+16%) and BioPharmaceuticals. Product Sales were $26.7 bn (+10%), Alliance Revenue $1.3 bn (+38%). Core EPS reached $4.66 (+17%) and reported EPS $3.46 (+32%) as core operating profit advanced 13%.

Q2 2025: Revenue grew 11% CER to $14.5 bn; core EPS $2.17 (+12%). Gross margin 83%; reported operating margin 24% (core 32%). Key brands outperformed: Tagrisso $3.5 bn (+10%), Imfinzi $2.7 bn (+21%), Enhertu $1.3 bn (+38%) while Soliris (-30%) and Brilinta (-21%) declined.

Capital allocation & strategy: Interim dividend increased 3% to $1.03. AZN acquired cell-therapy firm EsoBiotec for up to $1 bn, signed a $110 m upfront AI-drug-discovery deal with CSPC (milestones up to $5.2 bn) and announced a $50 bn US manufacturing/R&D investment, including a new Virginia drug-substance plant.

R&D momentum: 12 positive Phase III readouts (e.g., baxdrostat BaxHTN, Tagrisso FLAURA2) and 19 approvals. Pipeline breadth reinforced by oncology, CVRM and rare-disease advances.

Guidance reaffirmed: 2025 total revenue to grow high-single-digits and core EPS low-double-digits (CER); FX now seen broadly neutral. Core tax rate 18-22%.

AstraZeneca (AZN) reports that baxdrostat, its orally administered, first-in-class aldosterone synthase inhibitor, met the primary and all secondary endpoints in the pivotal Phase III BaxHTN trial involving 796 patients with uncontrolled or treatment-resistant hypertension. At both 2 mg and 1 mg doses, baxdrostat produced a statistically significant, clinically meaningful reduction in mean seated systolic blood pressure (SBP) at 12 weeks versus placebo when added to standard of care. The compound was 鈥済enerally well tolerated鈥� and showed a favourable safety profile. Additional endpoints鈥攊ncluding diastolic BP, SBP in the resistant-hypertension subgroup, proportion of patients achieving SBP <130 mmHg, and persistence of effect during a randomised withdrawal period鈥攚ere all achieved.

The BaxHTN study comprises three components: (1) a 12-week double-blind efficacy period, (2) an 8-week withdrawal test of durability, and (3) a 52-week safety follow-up. Data will be shared with regulators worldwide and presented during a late-breaking Hot Line session at the European Society of Cardiology Congress in August 2025.

Hypertension affects 1.3 billion people globally, and roughly half of U.S. patients on multiple drugs remain uncontrolled, underlining the addressable market. By specifically targeting aldosterone鈥攊mplicated in difficult-to-manage hypertension鈥攂axdrostat introduces a novel mechanism to a therapeutic area with limited innovation in two decades.

AstraZeneca obtained baxdrostat through its February 2023 acquisition of CinCor Pharma; a contingent value right of $10 per CinCor share (鈮�$0.5 billion) becomes payable upon NDA/MAA submission. Positive Phase III results substantially de-risk that milestone and accelerate the path toward regulatory filings.

AstraZeneca PLC (AZN) has secured European Commission approval for Imfinzi (durvalumab) as the first and only peri-operative immunotherapy for resectable muscle-invasive bladder cancer (MIBC). The label covers combination use with gemcitabine/cisplatin before radical cystectomy and Imfinzi monotherapy after surgery. Approval is based on the NIAGARA Phase III trial, where the Imfinzi regimen produced a 32% reduction in risk of disease progression/recurrence or death (EFS HR 0.68; p<0.0001) and a 25% reduction in overall mortality (OS HR 0.75; p = 0.0106) versus neoadjuvant chemotherapy alone. Two-year event-free and overall survival rates reached 67.8% and 82.2%, respectively, compared with 59.8% and 75.2% for the control arm.

Safety signals were consistent with known profiles; the addition of Imfinzi did not hinder surgical completion. The regimen received the highest 鈥淎鈥� grade on ESMO鈥檚 Magnitude of Clinical Benefit Scale, highlighting strong clinical value.

Commercially, the EU market represents more than 35,000 treated MIBC patients annually. Given Imfinzi鈥檚 prior U.S. approval and ongoing filings in Japan and other regions, the decision materially enlarges the drug鈥檚 addressable population and strengthens 础蝉迟谤补窜别苍别肠补鈥檚 oncology franchise. Management states Imfinzi is positioned to 鈥渢ransform the standard of care,鈥� setting a new survival benchmark in a setting that has seen few therapeutic advances in decades.